ArticleNature methods2018
Efficient scarless genome editing in human pluripotent stem cells.
Article in Nature methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- CD8MedComm · 2026Review
- Megabase-scale loss of heterozygosity provoked by CRISPR-Cas9 DNA double-strand breaks.Molecular cell · 2025Article
- Age-Related Macular Degeneration: Therapeutic Strategies Based on Stem Cells.Stem cell reviews and reports · 2025Review
- Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells.Scientific reports · 2025Article
- Article
- Lineage-tracing hematopoietic stem cell origins in vivo to efficiently make human HLF+ HOXA+ hematopoietic progenitors from pluripotent stem cells.Developmental cell · 2024Article
- Bacterial genome engineering using CRISPR-associated transposases.Nature protocols · 2024Review
- Scarless genome editing technology and its application to crop improvement.Breeding science · 2024Article
- iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer.Cell reports. Medicine · 2023Article
- Integration of xeno-free single-cell cloning in CRISPR-mediated DNA editing of human iPSCs improves homogeneity and methodological efficiency of cellular disease modeling.Stem cell reports · 2023Article
- Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9.Nature communications · 2023Article
- Bacterial genome engineering using CRISPR RNA-guided transposases.bioRxiv : the preprint server for biology · 2023Article
- Detection of unintended on-target effects in CRISPR genome editing by DNA donors carrying diagnostic substitutions.Nucleic acids research · 2023Article
- Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders.Neuroscience applied · 2023Review
- Selecting for CRISPR-Edited Knock-In Cells.International journal of molecular sciences · 2022Review
- Biallelic and gene-wide genomic substitution for endogenous intron and retroelement mutagenesis in human cells.Nature communications · 2022Article
- CRISPR Del/Rei: a simple, flexible, and efficient pipeline for scarless genome editing.Scientific reports · 2022Article
- Cas9-induced large deletions and small indels are controlled in a convergent fashion.Nature communications · 2022Article
- Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls.Stem cell reports · 2022Article
- Efficient gene editing through an intronic selection marker in cells.Cellular and molecular life sciences : CMLS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scarless genome editing in human pluripotent stem cells (hPSCs) represents a goal for both precise research applications and clinical translation of hPSC-derived therapies. Here we established a versatile and efficient method that combines CRISPR-Cas9-mediated homologous recombination with positive-negative selection of edited clones to generate scarless genetic changes in hPSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.